<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227773</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000446076</org_study_id>
    <secondary_id>ECOG-E6203</secondary_id>
    <nct_id>NCT00227773</nct_id>
  </id_info>
  <brief_title>Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control&#xD;
      symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide&#xD;
      may be an effective treatment for neuroendocrine tumors.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide&#xD;
      works in treating patients with progressive neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the 4-month progression-free and overall survival of patients with progressive&#xD;
           low-grade neuroendocrine tumors treated with vatalanib and octreotide.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the effect of this regimen on tumor markers (e.g., chromogranin A, 5-HIAA, and&#xD;
           gastrin) in these patients.&#xD;
&#xD;
        -  Determine the toxicity and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral vatalanib once daily on days 1- 28 and octreotide* intramuscularly or&#xD;
      IV on day 1. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Patients on a stable dose (i.e., no changes in dosage within the past 3 months) of&#xD;
      octreotide before study entry remain on their current dose and schedule during study&#xD;
      participation; patients who experience hypersensitivity and/or toxicity to octreotide may&#xD;
      receive vatalanib alone.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks, every 3 months for 2&#xD;
      years, and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octreotide acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatalanib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiangiogenesis therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>growth factor antagonist therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hormone therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>protein tyrosine kinase inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>somatostatin analogue therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed low-grade neuroendocrine tumors&#xD;
&#xD;
          -  The following tumor types are excluded:&#xD;
&#xD;
          -  Small cell lung cancer&#xD;
&#xD;
          -  Medullary thyroid cancer&#xD;
&#xD;
          -  Paraganglioma&#xD;
&#xD;
          -  Pheochromocytoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Radiographic evidence of disease progression after completion of any prior systemic&#xD;
             therapy, chemoembolization, bland embolization, or observation within the past year,&#xD;
             defined as either of the following:&#xD;
&#xD;
          -  Appearance of a new lesion&#xD;
&#xD;
          -  At least 20% increase in the longest diameter (LD) of any previously documented lesion&#xD;
             or an increase in the sum of the LDs of multiple lesions in the aggregate of 20%&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
          -  Urine protein negative by dipstick&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; 1.0&#xD;
&#xD;
          -  Urine protein &lt; 1 g by 24-hour urine collection&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
          -  No ulcerative disease&#xD;
&#xD;
          -  No uncontrolled nausea, vomiting, or diarrhea&#xD;
&#xD;
          -  No bowel obstruction&#xD;
&#xD;
          -  No other gastrointestinal tract disease resulting in an inability to take oral&#xD;
             medication&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be able to receive a contrast-enhanced CT scan&#xD;
&#xD;
          -  No known history of allergic reaction to vatalanib or its derivatives or octreotide&#xD;
             injections&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen&#xD;
&#xD;
          -  Chemoembolization is not considered systemic chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since other prior systemic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior local liver therapy&#xD;
&#xD;
          -  No prior anti-vascular endothelial growth factor agents&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice&#xD;
&#xD;
          -  No concurrent therapeutic warfarin or similar oral anticoagulants that are metabolized&#xD;
             by the cytochrome P450 system&#xD;
&#xD;
          -  Concurrent heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle Holen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Mulcahy, MD</last_name>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <keyword>localized gastrointestinal carcinoid tumor</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>somatostatinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

